Prima creates new R&D role

Prima Biomed (ASX:PRR) today announced it had created a new research and development position to support its commercialisation abilities.

Dr John Bates, formerly of Ernst and Young, has been appointed the company's research and development manager.

Revealing the appointment, chief executive officer Marcus Clark said the new role reflected the company's rapid rate of development of its existing portfolio of investment projects.

"John's background in R&D management and commercialisation with CSL Limited, where he oversaw the development of adjuvanted human vaccines, provides him with considerable strengths in the successful management of pharmaceutical product development," Clark said.

"His more recent experience with Ernst & Young, where he held a senior management position in the professional services practice for technology assessment, development and commercialisation has broadened his skills in the commercialisation phases of product development."

He said Bates' experience would ensure the efficient development of Prima's immunotherapy and vaccine projects, while his extensive networks would form a useful part of the company's commercialisation strategies.

"I am sure he will add great value to the company and complement the team at what is a very important time for us," Clark said.

He said the company was set to begin plans for the next stage of its three-year programs involving subsidiary companies Arthron and Cancer Vac.

"In addition, we have commenced the R&D program for the DCtag (vaccine platform) technology under the newly formed company Panvax Ltd," Clark said.

"This program has tremendous potential and needs very effective and active management in order to demonstrate proof of concept and achieve other results within the first 12 months."

Bates holds a science honours degree from the University of Melbourne, and completed his doctorate at the Walter and Eliza Hall Institute.